{"id":7710,"date":"2025-06-27T17:02:14","date_gmt":"2025-06-27T14:02:14","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7710"},"modified":"2025-06-27T17:02:14","modified_gmt":"2025-06-27T14:02:14","slug":"first-in-human-use-of-the-accucinch-device-for-lv-restoration-in-hfref-corcinch-hf-trial-begins","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/first-in-human-use-of-the-accucinch-device-for-lv-restoration-in-hfref-corcinch-hf-trial-begins\/","title":{"rendered":"First-in-Human Use of the AccuCinch Device for LV Restoration in HFrEF: CORCINCH-HF Trial Begins."},"content":{"rendered":"<div>First-in-Human Use of the AccuCinch Device for LV Restoration in HFrEF: CORCINCH-HF Trial Begins.<\/div>\n<div><\/div>\n<div>Transcatheter Device Targets LV Remodeling in HFrEF, Marking a New Direction in Structural Heart Failure Therapies<\/div>\n<div>Overview:<\/div>\n<div><\/div>\n<div>Announced in a clinical release dated June 23, 2025, as part of ongoing coverage of the CORCINCH-HF pivotal trial, the first patient has been treated using the investigational AccuCinch Ventricular Restoration System.<\/div>\n<div><\/div>\n<div>Key Scientific Highlights:<\/div>\n<div><span> 1. Study Name:<\/span><\/div>\n<div>CORCINCH-HF \u2013 a U.S. pivotal trial evaluating a novel transcatheter therapy for patients with heart failure with reduced ejection fraction (HFrEF).<\/div>\n<div><span> 2. Device:<\/span><\/div>\n<div>AccuCinch Ventricular Restoration System (Ancora Heart, Inc.), designed to reduce LV size, lower wall stress, and improve myocardial function.<\/div>\n<div><span> 3. Mechanism:<\/span><\/div>\n<div>Aims to achieve reverse remodeling of the enlarged left ventricle using a transcatheter approach rather than surgery or pharmacologic therapy.<\/div>\n<div><span> 4. Milestone:<\/span><\/div>\n<div>First patient successfully treated in the U.S. Trial will enroll 250 randomized symptomatic HFrEF patients.<\/div>\n<div><span> 5. Trial Leadership:<\/span><\/div>\n<div>Dr. Ulrich Jorde (Montefiore Health System, affiliated with Albert Einstein College of Medicine)<\/div>\n<div>Dr. Mark Reisman (Weill Cornell Medical Center, affiliated with Cornell University)<\/div>\n<div><span> 6. Regulatory Status:<\/span><\/div>\n<div>Granted FDA Breakthrough Device Designation in 2022.<\/div>\n<div><span> 7. Preliminary Data:<\/span><\/div>\n<div>Early results presented at THT 2023 and published in the Journal of Cardiac Failure showed favorable safety and feasibility.<\/div>\n<div><span> 8. Next Steps:<\/span><\/div>\n<div>Six-month follow-up data will support the PMA submission to the FDA. Trial endpoints include safety, structural remodeling, symptom improvement, and hospitalization reduction.<\/div>\n<div><span> 9. Significance:<\/span><\/div>\n<div>AccuCinch is the first transcatheter device specifically targeting LV restoration in HFrEF patients unresponsive to guideline-directed medical therapy.<\/div>\n<div><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04331769\">https:\/\/clinicaltrials.gov\/study\/NCT04331769<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First-in-Human Use of the AccuCinch Device for LV Restoration in HFrEF: CORCINCH-HF Trial Begins. Transcatheter Device Targets LV Remodeling in HFrEF, Marking a New Direction in Structural Heart Failure Therapies Overview: Announced in a clinical release dated June 23, 2025, as part of ongoing coverage of the CORCINCH-HF pivotal trial, the first patient has been [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7710","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7710"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7710\/revisions"}],"predecessor-version":[{"id":7714,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7710\/revisions\/7714"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}